China

sea water forming seafoams

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer

SHANGHAI, June 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr. Mike Berry has been appointed Chief Technology Officer, effective immediately.

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the entire value chain of the pharmaceutical industry, announced the clinical trial application of its self-developed 9MW3811 injection for idiopathic pulmonary fibrosis has been approved by the United States Food and Drug Administration (FDA)

laboratory test tubes

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration).

unrecognizable chemist taking liquid with pipette from test tube in modern laboratory

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.

red and blue water droplets

Chinese Drugmakers March Into Africa Seeking New Business Foothold

Chinese pharmaceutical companies are gearing up a foray into Africa with multibillion-yuan investments in local drugmaking facilities, lured by the unmet health-care needs of the world's fastest growing and most underserved continent.

photo of golden cogwheel on black background

Xi Jinping meets Bill Gates in China, calls him ‘an old friend’

BEIJING, June 16 (Reuters) - Chinese President Xi Jinping called Bill Gates "an old friend" and said he hoped they could cooperate in a way that would benefit both China and the United States, in Xi's first meeting with a foreign entrepreneur in years.

body of water beside beach sand

Hong Kong’s VMS Group eyes up to $400m for flagship PE fund

Hong Kong alternative asset management firm VMS Group is targeting $300 million for its flagship private equity fund, with a hard cap of $400 million.

group of person sitting indoors

Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited

SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is in advanced discussion with its Company's Chairman and Chief Executive Officer, Mr. Hong Zhida, to acquire Mr Hong's partial stake in Shanghai Bao Pharmaceutical Company Limited.

time lapse photography of flowing waterfall

Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million

On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.

macbook on table

Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca

SHANGHAI, June 16, 2023 /PRNewswire/ -- Cholesgen (Shanghai) Co.Ltd. ('Cholesgen') today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca.